These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38741503)

  • 1. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
    Suzuki S
    Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Features of Myasthenia Gravis as an Immune-related Adverse Event].
    Suzuki S
    Brain Nerve; 2024 Jan; 76(1):27-32. PubMed ID: 38191136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
    Seki M; Kitano S; Suzuki S
    Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
    Seki M; Suzuki S
    Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral nervous system immune-related adverse events due to checkpoint inhibition.
    O'Hare M; Guidon AC
    Nat Rev Neurol; 2024 Sep; 20(9):509-525. PubMed ID: 39122934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
    Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
    J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
    Salim A; Tapia Rico G; Shaikh A; Brown MP
    Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
    [No Abstract]   [Full Text] [Related]  

  • 11. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
    Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
    Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.
    Seligman C; Chang YM; Luo J; Garden OA
    Front Neurol; 2022; 13():1004810. PubMed ID: 36698907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysautonomia associated with immune checkpoint inhibitors.
    Tezuka T; Okuzumi S; Nakashima C; Ide T; Imai S; Mitsuboshi S; Kuwahara Y; Takizawa T; Seki M; Minematsu N; Aragane N; Nakahara J; Hori S; Nakane S; Suzuki S
    J Neurol; 2023 Jul; 270(7):3413-3423. PubMed ID: 36939931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
    Villagrán-García M; Velasco R
    Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases.
    Gra M; Pham-Ledard A; Gerard E; Dutriaux C; Beylot-Barry M; Duval F; Carla L; Soulages A; Prey S
    J Immunother; 2023 Sep; 46(7):276-278. PubMed ID: 37326491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.